Join
Live feed
·
PRReleasevia Quantisnow
Apellis Pharmaceuticals Inc. logo

Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU

ByQuantisnow·Wall Street's wire, on your screen.
APLS· Apellis Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track APLS (Apellis Pharmaceuticals Inc.) and more on Quantisnow.